Patents by Inventor Fredrick F. Van Goor

Fredrick F. Van Goor has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Pharmaceutical Compositions for the Treatment of CFTR-Mediated Disorders
    Publication number: 20160200684
    Abstract: The present invention relates to the use of N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide (Compound 1), solids forms, and pharmaceutical compositions thereof for the treatment of CFTR-mediated diseases, particularly cystic fibrosis, in patients possessing specific genetic mutations. The present invention also relates to the use of Compound 1 in combination with 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid (Compound 2), and Compound 1 in combination with (S)-1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl)cyclopropanecarboxamide (Compound 3), for the treatment of CFTR-mediated diseases, particularly cystic fibrosis, in patients possessing specific genetic mutations.
    Type: Application
    Filed: November 26, 2014
    Publication date: July 14, 2016
    Applicant: Vertex Pharmaceuticals Incorporated
    Inventors: Fredrick F. Van Goor, William Lawrence Burton, Haihul Yu, Beth Jennifer Hoffman
  • Process for making modulators of cystic fibrosis transmembrane conductance regulator
    Patent number: 9371287
    Abstract: The invention provides a process for the preparation of a compound of Formula 1, comprising coupling a carboxylic acid of Formula 2 with an aniline of Formula 3 in the presence of a coupling agent.
    Type: Grant
    Filed: May 23, 2014
    Date of Patent: June 21, 2016
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: John DeMattei, Adam R. Looker, Bobbianna Neubert-Langille, Martin Trudeau, Stefanie Roeper, Michael P. Ryan, Dahrika Milfred Yap Guerette, Brian R. Krueger, Peter D. J. Grootenhuis, Fredrick F. Van Goor, Martyn C. Botfield, Gregor Zlokarnik
  • CORRECTORS ACTING THROUGH MSD1 OF CFTR PROTEIN
    Publication number: 20160074374
    Abstract: The present disclosure provides methods for treating Cystic Fibrosis in a subject by administering to the subject a corrector agent capable of acting through MSD1 during the biosynthesis of CFTR protein. The disclosure also provides methods of screening for new corrector agents capable of acting through MSD1 during the biosynthesis of a CFTR protein.
    Type: Application
    Filed: April 25, 2014
    Publication date: March 17, 2016
    Inventors: Fredrick F. Van Goor, Beth Jennifer Hoffman, Oxana Adolfovna de la Rosa, Douglas Cyr
  • PHARMACEUTICAL COMPOSITIONS AND ADMINISTRATIONS THEREOF
    Publication number: 20160067239
    Abstract: The present invention relates to pharmaceutical compositions comprising a compound of Formula I in combination with one or both of a Compound of Formula II and/or a Compound of Formula III. The invention also relates to solid forms and to pharmaceutical formulations thereof, and to methods of using such compositions in the treatment of CFTR mediated diseases, particularly cystic fibrosis.
    Type: Application
    Filed: January 23, 2015
    Publication date: March 10, 2016
    Inventors: Fredrick F. Van Goor, Rossitza Gueorguieva Alargova, Tim Edward Alcacio, Sneha G. Arekar, Steven C. Johnston, Irina Nikolaevna Kadiyala, Ali Keshavarz-Shokri, Mariusz Krawiec, Elaine Chungmin Lee, Ales Medek, Praveen Mudunuri, Mark Jeffrey Sullivan, Noreen Tasneem Zaman, Beili Zhang, Yuegang Zhang, Gregor Zlokarnik
  • CORRECTORS ACTING THROUGH MSD1 OF CFTR PROTEIN
    Publication number: 20160030406
    Abstract: The present disclosure provides methods for treating Cystic Fibrosis in a subject by administering to the subject a corrector agent capable of acting through MSD1 during the biosynthesis of CFTR protein. The disclosure also provides methods of screening for new corrector agents capable of acting through MSD1 during the biosynthesis of a CFTR protein.
    Type: Application
    Filed: March 14, 2014
    Publication date: February 4, 2016
    Inventors: Fredrick F. Van Goor, Beth Jennifer Hoffman, Oxana Adolfovna de la Rosa, Douglas Cyr
  • Pharmaceutical Compositions and Administrations Thereof
    Publication number: 20160022664
    Abstract: The present invention relates to pharmaceutical compositions comprising a compound of Formula I in combination with one or both of a Compound of Formula II and/or a Compound of Formula III. The invention also relates to solid forms and to pharmaceutical formulations thereof, and to methods of using such compositions in the treatment of CFTR mediated diseases, particularly cystic fibrosis.
    Type: Application
    Filed: February 23, 2015
    Publication date: January 28, 2016
    Inventors: Fredrick F. Van Goor, Rossitza Gueorguieva Alargova, Tim Edward Alcacio, Hayley Marie Binch, Martyn Curtis Botfield, Lev Tyler Dewey Fanning, Peter Diederik Jan Grootenhuis, Dennis James Hurley, Irina Nikolaevna Kadiyala, Ritu Rohit Kaushik, Ali Keshavarz-Shokri, Mariusz Krawiec, Elaine Chungmin Lee, Brian Luisi, Ales Medek, Mehdi Numa, Urvi Jagdishbhai Sheth, Alina Silina, Marinus Jacobus Verwijs, Xiaoqing Yang, Christopher Ryan Young, Noreen Tasneem Zaman, Beili Zhang, Yuegang Zhang, Gregor Zlokarnik
  • Pharmaceutical Compositions and Administrations Thereof
    Publication number: 20160022665
    Abstract: The present invention relates to pharmaceutical compositions comprising a compound of Formulas I and II, optionally in combination with a Compound of Formula III and/or a Compound of Formula IV. The invention also relates to solid forms and to pharmaceutical formulations thereof, and to methods of using such compositions in the treatment of CFTR mediated diseases, particularly cystic fibrosis.
    Type: Application
    Filed: February 25, 2015
    Publication date: January 28, 2016
    Inventors: Fredrick F. Van Goor, Rossitza Gueorguieva Alargova, Tim Edward Alcacio, Sneha G. Arekar, Hayley Marie Binch, Martyn Curtis Botfield, Lev Tyler Dewey Fanning, Peter Diederik Jan Grootenhuis, Dennis James Hurley, Steven C. Johnston, Irina Nikolaevna Kadiyala, Ritu Rohit Kaushik, Ali Keshavarz-Shokri, Mariusz Krawiec, Elaine Chungmin Lee, Brian Luisi, Ales Medek, Praveen Mudunuri, Mehdi Numa, Urvi Jagdishbhai Sheth, Alina Silina, Mark Jeffrey Sullivan, Marinus Jacobus Verwijs, Xiaoqing Yang, Christopher Ryan Young, Noreen Tasneem Zaman, Beili Zhang, Yuegang Zhang, Gregor Zlokarnik
  • Pharmaceutical Compositions for the Treatment of CFTR-Mediated Disorders
    Publication number: 20150315152
    Abstract: The present invention relates to the use of N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide (Compound 1), solids forms, and pharmaceutical compositions thereof for the treatment of CFTR-mediated diseases, particularly cystic fibrosis, in patients possessing specific genetic mutations. The present invention also relates to the use of Compound 1 in combination with 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid (Compound 2), and Compound 1 in combination with (S)-1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl)cyclopropanecarboxamide (Compound 3), for the treatment of CFTR-mediated diseases, particularly cystic fibrosis, in patients possessing specific genetic mutations.
    Type: Application
    Filed: November 26, 2014
    Publication date: November 5, 2015
    Inventors: Fredrick F. Van Goor, William Lawrence Burton, Haihui Yu, Beth Jennifer Hoffman
  • PROCESS FOR MAKING MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR
    Publication number: 20150315151
    Abstract: The invention provides a process for the preparation of a compound of Formula 1, comprising coupling a carboxylic acid of Formula 2 with an aniline of Formula 3 in the presence of a coupling agent.
    Type: Application
    Filed: May 23, 2014
    Publication date: November 5, 2015
    Inventors: John DeMattei, Adam R. Looker, Bobbianna Neubert-Langille, Martin Trudeau, Stefanie Roeper, Michael P. Ryan, Dahrika Milfred Yap Guerette, Brian R. Krueger, Peter D.J. Grootenhuis, Fredrick F. Van Goor, Martyn C. Botfield, Gregor Zlokarnik
  • COMPOUNDS USEFUL IN CFTR ASSAYS AND METHODS THEREWITH
    Publication number: 20150293078
    Abstract: The present invention relates to compounds useful in CFTR assays. The present invention also relates to compounds useful in monitoring CFTR activity in therapies for CFTR-mediated diseases. The present invention also provides an assay for use in measuring CFTR correction.
    Type: Application
    Filed: April 17, 2015
    Publication date: October 15, 2015
    Inventors: Ashvani K. Singh, Fredrick F. Van Goor, Jennings Franklin Worley, III, Thomas Knapp
  • Compositions for Treatment of Cystic Fibrosis and Other Chronic Diseases
    Publication number: 20150231142
    Abstract: The present invention relates to pharmaceutical compositions comprising an inhibitor of epithelial sodium channel activity in combination with at least one ABC Transporter modulator compound of Formula A, Formula B, Formula C, or Formula D. The invention also relates to pharmaceutical formulations thereof, and to methods of using such compositions in the treatment of CFTR mediated diseases, particularly cystic fibrosis using the pharmaceutical combination compositions.
    Type: Application
    Filed: April 17, 2015
    Publication date: August 20, 2015
    Inventors: Fredrick F. Van Goor, William Lawrence Burton
  • MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS
    Publication number: 20150174098
    Abstract: Compounds of the present invention and pharmaceutically acceptable compositions thereof, are useful as modulators of ATP-Binding Cassette (“ABC”) transporters or fragments thereof, including Cystic Fibrosis Transmembrane Conductance Regulator (“CFTR”). The present invention also relates to methods of treating ABC transporter mediated diseases using compounds of the present invention.
    Type: Application
    Filed: December 22, 2014
    Publication date: June 25, 2015
    Inventors: SARA SABINA HADIDA RUAH, PETER DIEDERIK JAN GROOTENHUIS, FREDRICK F. VAN GOOR, JINGLAN ZHOU, BRIAN RICHARD BEAR, MARK THOMAS MILLER, JASON McCARTNEY, MEHDI NUMA, XIAOQING YANG
  • Pharmaceutical Compositions and Administrations Thereof
    Publication number: 20150164881
    Abstract: The present invention relates to pharmaceutical compositions comprising a compound of Formula I in combination with one or both of a Compound of Formula II and/or a Compound of Formula III. The invention also relates to solid forms and to pharmaceutical formulations thereof, and to methods of using such compositions in the treatment of CFTR mediated diseases, particularly cystic fibrosis.
    Type: Application
    Filed: February 23, 2015
    Publication date: June 18, 2015
    Inventors: Fredrick F. Van Goor, Rossitza Gueorguieva Alargova, Tim Edward Alcacio, Hayley Marie Binch, Martyn Curtis Botfield, Lev Tyler Dewey Fanning, Peter Diederik Jan Grootenhuis, Dennis James Hurley, Irina Nikolaevna Kadiyala, Ritu Rohit Kaushik, Ali Keshavarz-Shokri, Mariusz Krawiec, Elaine Chungmin Lee, Brian Luisi, Ales Medek, Mehdi Numa, Urvi Jagdishbhai Sheth, Alina Silina, Marinus Jacobus Verwijs, Xiaoqing Yang, Christopher Ryan Young, Noreen Tasneem Zaman, Beili Zhang, Yuegang Zhang, Gregor Zlokarnik
  • PHARMACEUTICAL COMPOSITIONS AND ADMINISTRATIONS THEREOF
    Publication number: 20150164883
    Abstract: The present invention relates to pharmaceutical compositions comprising a compound of Formulas I and II, optionally in combination with a Compound of Formula III and/or a Compound of Formula IV. The invention also relates to solid forms and to pharmaceutical formulations thereof, and to methods of using such compositions in the treatment of CFTR mediated diseases, particularly cystic fibrosis.
    Type: Application
    Filed: February 25, 2015
    Publication date: June 18, 2015
    Inventors: Fredrick F. Van Goor, Rossitza Gueorguieva Alargova, Tim Edward Alcacio, Sneha G. Arekar, Hayley Marie Binch, Martyn Curtis Botfield, Lev Tyler Dewey Fanning, Peter Diederik Jan Grootenhuis, Dennis James Hurley, Steven C. Johnston, Irina Nikolaevna Kadiyala, Ritu Rohit Kaushik, Ali Keshavarz-Shokri, Mariusz Krawiec, Elaine Chungmin Lee, Brian Luisi, Ales Medek, Praveen Mudunuri, Mehdi Numa, Urvi Jagdishbhai Sheth, Alina Silina, Mark Jeffrey Sullivan, Marinus Jacobus Verwijs, Xiaoqing Yang, Christopher Ryan Young, Noreen Tasneem Zaman, Beili Zhang, Yuegang Zhang, Gregor Zlokmik
  • Compositions for Treatment of Cystic Fibrosis and Other Chronic Diseases
    Publication number: 20150150879
    Abstract: The present invention relates to pharmaceutical compositions comprising an inhibitor of epithelial sodium channel activity in combination with at least one ABC Transporter modulator compound of Formula A, Formula B, Formula C, or Formula D. The invention also relates to pharmaceutical formulations thereof, and to methods of using such compositions in the treatment of CFTR mediated diseases, particularly cystic fibrosis using the pharmaceutical combination compositions.
    Type: Application
    Filed: December 16, 2013
    Publication date: June 4, 2015
    Inventors: Fredrick F. Van Goor, William Lawrence Burton
  • PHARMACEUTICAL COMPOSITIONS AND ADMINISTRATIONS THEREOF
    Publication number: 20150141459
    Abstract: The present invention relates to pharmaceutical compositions comprising a compound of Formula I in combination with one or both of a Compound of Formula II and/or a Compound of Formula III. The invention also relates to solid forms and to pharmaceutical formulations thereof, and to methods of using such compositions in the treatment of CFTR mediated diseases, particularly cystic fibrosis.
    Type: Application
    Filed: January 23, 2015
    Publication date: May 21, 2015
    Inventors: Fredrick F. Van Goor, Rossitza Gueorguieva Alargova, Tim Edward Alcacio, Sneha G. Arekar, Steven C. Johnston, Irina Nikolaevna Kadiyala, Ali Keshavarz-Shokri, Mariusz Krawiec, Elaine Chungmin Lee, Ales Medek, Praveen Mudunuri, Mark Jeffrey Sullivan, Noreen Tasneem Zaman, Beili Zhang, Yuegang Zhang, Gregor Zlokarnik
  • Modulators of ATP-Binding Cassette Transporters
    Publication number: 20150094304
    Abstract: Compounds of the present invention and pharmaceutically acceptable compositions thereof, are useful as modulators of ATP-Binding Cassette (“ABC”) transporters or fragments thereof, including Cystic Fibrosis Transmembrane Conductance Regulator (“CFTR”). The present invention also relates to methods of treating ABC transporter mediated diseases using compounds of the present invention.
    Type: Application
    Filed: December 11, 2014
    Publication date: April 2, 2015
    Inventors: SARA SABINA HADIDA RUAH, PETER DIEDERIK JAN GROOTENHUIS, FREDRICK F. VAN GOOR, JINGLAN ZHOU, BRIAN RICHARD BEAR, MARK THOMAS MILLER, JASON MC CARTNEY, MEHDI MICHEL DJAMEL NUMA
  • PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF CFTR-MEDIATED DISORDERS
    Publication number: 20150080431
    Abstract: The present invention relates to the use of N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide (Compound 1), solids forms, and pharmaceutical compositions thereof for the treatment of CFTR-mediated diseases, particularly cystic fibrosis, in patients possessing specific genetic mutations. The present invention also relates to the use of Compound 1 in combination with 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid (Compound 2), and Compound 1 in combination with (S)-1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl)cyclopropanecarboxamide (Compound 3), for the treatment of CFTR-mediated diseases, particularly cystic fibrosis, in patients possessing specific genetic mutations.
    Type: Application
    Filed: November 26, 2014
    Publication date: March 19, 2015
    Inventors: Fredrick F. Van Goor, William Lawrence Burton, Haihui Yu, Beth Jennifer Hoffman
  • PROCESS FOR MAKING MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR
    Publication number: 20150073015
    Abstract: The invention provides a process for the preparation of a compound of Formula 1, comprising coupling a carboxylic acid of Formula 2 with an aniline of Formula 3 in the presence of a coupling agent.
    Type: Application
    Filed: May 23, 2014
    Publication date: March 12, 2015
    Inventors: John DeMattei, Adam R. Looker, Bobbianna Neubert-Langille, Martin Trudeau, Stefanie Roeper, Michael P. Ryan, Dahrika Milfred Yap Guerette, Brian R. Krueger, Peter D.J. Grootenhuis, Fredrick F. Van Goor, Martyn C. Botfield, Gregor Zlokarnik
  • Modulators of ATP-binding cassette transporters
    Patent number: 8952050
    Abstract: Compounds of the present invention and pharmaceutically acceptable compositions thereof, are useful as modulators of ATP-Binding Cassette (“ABC”) transporters or fragments thereof, including Cystic Fibrosis Transmembrane Conductance Regulator (“CFTR”). The present invention also relates to methods of treating ABC transporter mediated diseases using compounds of the present invention.
    Type: Grant
    Filed: September 25, 2013
    Date of Patent: February 10, 2015
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: Sara Sabina Hadida Ruah, Peter Diederik Jan Grootenhuis, Fredrick F. Van Goor, Jinglan Zhou, Brian Richard Bear, Mark Thomas Miller, Jason McCartney, Mehdi Numa, Xiaoqing Yang